Cargando…
Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
PURPOSE: ALK-activating mutations are identified in approximately 10% of newly diagnosed neuroblastomas and ALK amplifications in a further 1%–2% of cases. Lorlatinib, a third-generation anaplastic lymphoma kinase (ALK) inhibitor, will soon be given alongside induction chemotherapy for children with...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068437/ https://www.ncbi.nlm.nih.gov/pubmed/36602782 http://dx.doi.org/10.1158/1078-0432.CCR-22-2274 |
_version_ | 1785018673815093248 |
---|---|
author | Tucker, Elizabeth R. Jiménez, Irene Chen, Lindi Bellini, Angela Gorrini, Chiara Calton, Elizabeth Gao, Qiong Che, Harvey Poon, Evon Jamin, Yann Martins Da Costa, Barbara Barker, Karen Shrestha, Sumana Hutchinson, J. Ciaran Dhariwal, Simran Goodman, Angharad Del Nery, Elaine Gestraud, Pierre Bhalshankar, Jaydutt Iddir, Yasmine Saberi-Ansari, Elnaz Saint-Charles, Alexandra Geoerger, Birgit Marques Da Costa, Maria Eugénia Pierre-Eugène, Cécile Janoueix-Lerosey, Isabelle Decaudin, Didier Nemati, Fariba Carcaboso, Angel M. Surdez, Didier Delattre, Olivier George, Sally L. Chesler, Louis Tweddle, Deborah A. Schleiermacher, Gudrun |
author_facet | Tucker, Elizabeth R. Jiménez, Irene Chen, Lindi Bellini, Angela Gorrini, Chiara Calton, Elizabeth Gao, Qiong Che, Harvey Poon, Evon Jamin, Yann Martins Da Costa, Barbara Barker, Karen Shrestha, Sumana Hutchinson, J. Ciaran Dhariwal, Simran Goodman, Angharad Del Nery, Elaine Gestraud, Pierre Bhalshankar, Jaydutt Iddir, Yasmine Saberi-Ansari, Elnaz Saint-Charles, Alexandra Geoerger, Birgit Marques Da Costa, Maria Eugénia Pierre-Eugène, Cécile Janoueix-Lerosey, Isabelle Decaudin, Didier Nemati, Fariba Carcaboso, Angel M. Surdez, Didier Delattre, Olivier George, Sally L. Chesler, Louis Tweddle, Deborah A. Schleiermacher, Gudrun |
author_sort | Tucker, Elizabeth R. |
collection | PubMed |
description | PURPOSE: ALK-activating mutations are identified in approximately 10% of newly diagnosed neuroblastomas and ALK amplifications in a further 1%–2% of cases. Lorlatinib, a third-generation anaplastic lymphoma kinase (ALK) inhibitor, will soon be given alongside induction chemotherapy for children with ALK-aberrant neuroblastoma. However, resistance to single-agent treatment has been reported and therapies that improve the response duration are urgently required. We studied the preclinical combination of lorlatinib with chemotherapy, or with the MDM2 inhibitor, idasanutlin, as recent data have suggested that ALK inhibitor resistance can be overcome through activation of the p53-MDM2 pathway. EXPERIMENTAL DESIGN: We compared different ALK inhibitors in preclinical models prior to evaluating lorlatinib in combination with chemotherapy or idasanutlin. We developed a triple chemotherapy (CAV: cyclophosphamide, doxorubicin, and vincristine) in vivo dosing schedule and applied this to both neuroblastoma genetically engineered mouse models (GEMM) and patient-derived xenografts (PDX). RESULTS: Lorlatinib in combination with chemotherapy was synergistic in immunocompetent neuroblastoma GEMM. Significant growth inhibition in response to lorlatinib was only observed in the ALK-amplified PDX model with high ALK expression. In this PDX, lorlatinib combined with idasanutlin resulted in complete tumor regression and significantly delayed tumor regrowth. CONCLUSIONS: In our preclinical neuroblastoma models, high ALK expression was associated with lorlatinib response alone or in combination with either chemotherapy or idasanutlin. The synergy between MDM2 and ALK inhibition warrants further evaluation of this combination as a potential clinical approach for children with neuroblastoma. |
format | Online Article Text |
id | pubmed-10068437 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Association for Cancer Research |
record_format | MEDLINE/PubMed |
spelling | pubmed-100684372023-04-04 Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models Tucker, Elizabeth R. Jiménez, Irene Chen, Lindi Bellini, Angela Gorrini, Chiara Calton, Elizabeth Gao, Qiong Che, Harvey Poon, Evon Jamin, Yann Martins Da Costa, Barbara Barker, Karen Shrestha, Sumana Hutchinson, J. Ciaran Dhariwal, Simran Goodman, Angharad Del Nery, Elaine Gestraud, Pierre Bhalshankar, Jaydutt Iddir, Yasmine Saberi-Ansari, Elnaz Saint-Charles, Alexandra Geoerger, Birgit Marques Da Costa, Maria Eugénia Pierre-Eugène, Cécile Janoueix-Lerosey, Isabelle Decaudin, Didier Nemati, Fariba Carcaboso, Angel M. Surdez, Didier Delattre, Olivier George, Sally L. Chesler, Louis Tweddle, Deborah A. Schleiermacher, Gudrun Clin Cancer Res Translational Cancer Mechanisms and Therapy PURPOSE: ALK-activating mutations are identified in approximately 10% of newly diagnosed neuroblastomas and ALK amplifications in a further 1%–2% of cases. Lorlatinib, a third-generation anaplastic lymphoma kinase (ALK) inhibitor, will soon be given alongside induction chemotherapy for children with ALK-aberrant neuroblastoma. However, resistance to single-agent treatment has been reported and therapies that improve the response duration are urgently required. We studied the preclinical combination of lorlatinib with chemotherapy, or with the MDM2 inhibitor, idasanutlin, as recent data have suggested that ALK inhibitor resistance can be overcome through activation of the p53-MDM2 pathway. EXPERIMENTAL DESIGN: We compared different ALK inhibitors in preclinical models prior to evaluating lorlatinib in combination with chemotherapy or idasanutlin. We developed a triple chemotherapy (CAV: cyclophosphamide, doxorubicin, and vincristine) in vivo dosing schedule and applied this to both neuroblastoma genetically engineered mouse models (GEMM) and patient-derived xenografts (PDX). RESULTS: Lorlatinib in combination with chemotherapy was synergistic in immunocompetent neuroblastoma GEMM. Significant growth inhibition in response to lorlatinib was only observed in the ALK-amplified PDX model with high ALK expression. In this PDX, lorlatinib combined with idasanutlin resulted in complete tumor regression and significantly delayed tumor regrowth. CONCLUSIONS: In our preclinical neuroblastoma models, high ALK expression was associated with lorlatinib response alone or in combination with either chemotherapy or idasanutlin. The synergy between MDM2 and ALK inhibition warrants further evaluation of this combination as a potential clinical approach for children with neuroblastoma. American Association for Cancer Research 2023-04-03 2023-01-05 /pmc/articles/PMC10068437/ /pubmed/36602782 http://dx.doi.org/10.1158/1078-0432.CCR-22-2274 Text en ©2023 The Authors; Published by the American Association for Cancer Research https://creativecommons.org/licenses/by-nc-nd/4.0/This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. |
spellingShingle | Translational Cancer Mechanisms and Therapy Tucker, Elizabeth R. Jiménez, Irene Chen, Lindi Bellini, Angela Gorrini, Chiara Calton, Elizabeth Gao, Qiong Che, Harvey Poon, Evon Jamin, Yann Martins Da Costa, Barbara Barker, Karen Shrestha, Sumana Hutchinson, J. Ciaran Dhariwal, Simran Goodman, Angharad Del Nery, Elaine Gestraud, Pierre Bhalshankar, Jaydutt Iddir, Yasmine Saberi-Ansari, Elnaz Saint-Charles, Alexandra Geoerger, Birgit Marques Da Costa, Maria Eugénia Pierre-Eugène, Cécile Janoueix-Lerosey, Isabelle Decaudin, Didier Nemati, Fariba Carcaboso, Angel M. Surdez, Didier Delattre, Olivier George, Sally L. Chesler, Louis Tweddle, Deborah A. Schleiermacher, Gudrun Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models |
title | Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models |
title_full | Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models |
title_fullStr | Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models |
title_full_unstemmed | Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models |
title_short | Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models |
title_sort | combination therapies targeting alk-aberrant neuroblastoma in preclinical models |
topic | Translational Cancer Mechanisms and Therapy |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068437/ https://www.ncbi.nlm.nih.gov/pubmed/36602782 http://dx.doi.org/10.1158/1078-0432.CCR-22-2274 |
work_keys_str_mv | AT tuckerelizabethr combinationtherapiestargetingalkaberrantneuroblastomainpreclinicalmodels AT jimenezirene combinationtherapiestargetingalkaberrantneuroblastomainpreclinicalmodels AT chenlindi combinationtherapiestargetingalkaberrantneuroblastomainpreclinicalmodels AT belliniangela combinationtherapiestargetingalkaberrantneuroblastomainpreclinicalmodels AT gorrinichiara combinationtherapiestargetingalkaberrantneuroblastomainpreclinicalmodels AT caltonelizabeth combinationtherapiestargetingalkaberrantneuroblastomainpreclinicalmodels AT gaoqiong combinationtherapiestargetingalkaberrantneuroblastomainpreclinicalmodels AT cheharvey combinationtherapiestargetingalkaberrantneuroblastomainpreclinicalmodels AT poonevon combinationtherapiestargetingalkaberrantneuroblastomainpreclinicalmodels AT jaminyann combinationtherapiestargetingalkaberrantneuroblastomainpreclinicalmodels AT martinsdacostabarbara combinationtherapiestargetingalkaberrantneuroblastomainpreclinicalmodels AT barkerkaren combinationtherapiestargetingalkaberrantneuroblastomainpreclinicalmodels AT shresthasumana combinationtherapiestargetingalkaberrantneuroblastomainpreclinicalmodels AT hutchinsonjciaran combinationtherapiestargetingalkaberrantneuroblastomainpreclinicalmodels AT dhariwalsimran combinationtherapiestargetingalkaberrantneuroblastomainpreclinicalmodels AT goodmanangharad combinationtherapiestargetingalkaberrantneuroblastomainpreclinicalmodels AT delneryelaine combinationtherapiestargetingalkaberrantneuroblastomainpreclinicalmodels AT gestraudpierre combinationtherapiestargetingalkaberrantneuroblastomainpreclinicalmodels AT bhalshankarjaydutt combinationtherapiestargetingalkaberrantneuroblastomainpreclinicalmodels AT iddiryasmine combinationtherapiestargetingalkaberrantneuroblastomainpreclinicalmodels AT saberiansarielnaz combinationtherapiestargetingalkaberrantneuroblastomainpreclinicalmodels AT saintcharlesalexandra combinationtherapiestargetingalkaberrantneuroblastomainpreclinicalmodels AT geoergerbirgit combinationtherapiestargetingalkaberrantneuroblastomainpreclinicalmodels AT marquesdacostamariaeugenia combinationtherapiestargetingalkaberrantneuroblastomainpreclinicalmodels AT pierreeugenececile combinationtherapiestargetingalkaberrantneuroblastomainpreclinicalmodels AT janoueixleroseyisabelle combinationtherapiestargetingalkaberrantneuroblastomainpreclinicalmodels AT decaudindidier combinationtherapiestargetingalkaberrantneuroblastomainpreclinicalmodels AT nematifariba combinationtherapiestargetingalkaberrantneuroblastomainpreclinicalmodels AT carcabosoangelm combinationtherapiestargetingalkaberrantneuroblastomainpreclinicalmodels AT surdezdidier combinationtherapiestargetingalkaberrantneuroblastomainpreclinicalmodels AT delattreolivier combinationtherapiestargetingalkaberrantneuroblastomainpreclinicalmodels AT georgesallyl combinationtherapiestargetingalkaberrantneuroblastomainpreclinicalmodels AT cheslerlouis combinationtherapiestargetingalkaberrantneuroblastomainpreclinicalmodels AT tweddledeboraha combinationtherapiestargetingalkaberrantneuroblastomainpreclinicalmodels AT schleiermachergudrun combinationtherapiestargetingalkaberrantneuroblastomainpreclinicalmodels |